InvestSMART

Radiopharm Theranostics Limited (ASX:RAD)

ALERT: Price-sensitive ASX Announcement for RAD
Current share price for RAD : $0.013 -0.015 (-52.73%)+
Announcement
Release
29 Aug 2025 11:37AM
Price at Release
$0.028
Full Release
download
Summary
Radiopharm Theranostics Limited's preliminary final report for the year ended 30 June 2025 indicates a significant increase in revenue from customer contracts by 1114.3% to $3,633,422, despite a decrease in overall loss after tax to $38,342,457 compared to the previous fiscal year. This improvement is attributed to a reduction in fair value movements in contingent consideration and share-based payments. The company's net assets rose to $42,871,904, largely due to capital inflows and tax incentives related to R&D activities. The report also notes an increase in ownership of Radiopharm Ventures from 51% to 75%. No dividends were declared for the year. The financial statements are in the process of being audited, with the audited report expected by September 2025.
Key Points
  • Revenue from contracts with customers increased by 1114.3% to $3,633,422.
  • Loss for the year reduced to $38,342,457.
  • Net assets increased to $42,871,904 due to capital raises and R&D tax incentives.
  • Ownership in Radiopharm Ventures increased to 75%.
  • No dividends declared for the financial year.
  • Financial statements are under audit, with results anticipated by September 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.